Unpublished findings from a recently halted hypertension treatment trial
has left some experts calling for changes to current guidelines for the control
of high blood pressure and others preaching caution about making such changes
until a detailed analysis of the new data is completed.
The source of the dispute is data from the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT), which was halted in December at the recommendation
of the trial’s independent data safety monitoring board when an interim
analysis of the data found that a newer treatment strategy of amlodipine (a
calcium channel blocker) and perindopril (an angiotensin-converting enzyme
inhibitor) was superior to the older treatment regimen of atenolol (a β-blocker)
and bendroflumethiazide (a thiazide diuretic).
Mitka M. Implications of Halted Study’s Findings for Hypertension Guidelines Unclear. JAMA. 2005;293(11):1312-1315. doi:10.1001/jama.293.11.1312